Spots Global Cancer Trial Database for EktoTherix™ Regenerative Tissue Scaffold for Repair of Surgical Excision Wounds

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: EktoTherix™ Regenerative Tissue Scaffold for Repair of Surgical Excision Wounds

Official Title: EktoTherix™ Regenerative Tissue Scaffold for Repair of Surgical Excision Wounds

Study ID: NCT02409628

Conditions

Non-melanoma Skin Cancer

Basal Cell Carcinoma

Squamous Cell Carcinoma

Interventions

EktoTherix

Study Description

Brief Summary: The purpose of study is to assess the safety and performance of EktoTherix™ Tissue Repair Scaffold in the treatment of full-thickness, dermatologic wounds created by the surgical removal of non-melanoma skin cancers. EktoTherix™ is a medical device developed by Neotherix Limited, manufactured by the polymer processing technique of electrospinning. Described as a "tissue scaffold", EktoTherix is placed into the surgical wound to help the patients' own cells repair the wound, enhancing healing and improving quality (including cosmetic outcome). The tissue scaffold is completely absorbed by the body during the healing process, which means that there is no need to remove it when the wound is healed. All patients recruited into this study are treated with EktoTherix, are seen weekly until they heal and seen again at the final follow-up visit three months post-surgery. The investigators hypothesise that the use of EktoTherix will increase incidence of complete healing and result in an overall better cosmetic result of the healed wound.

Detailed Description: